DOCSLIB.ORG

Annex 1 Referred to in Chapter 3 Schedules in Relation to Article 5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annex 1 Referred to in Chapter 3 Schedules in Relation to Article 5 Annex 1 referred to in Chapter 3 Schedules in relation to Article 5 Section 1 General Notes 1. For the purposes of Article 5, the following categories indicated in Column 4 and applicable terms and conditions set out in the notes indicated in Column 5 in each Party’s Schedule shall be applied: (a) Customs Duties on originating goods classified under the tariff items indicated with “A” shall be eliminated as from the date of entry into force of this Agreement; (b) Customs Duties on originating goods classified under the tariff items indicated with “B1” shall be the most-favored-nation applied rate as of April 1, 2003 as from the date of entry into force of this Agreement and such Customs Duties shall be eliminated as from April 1, 2006; (c) Customs Duties on originating goods classified under the tariff items indicated with “B2” shall be 0.5 yen per kilogram for Japan and 2.6 percent for Mexico as from the date of entry into force of this Agreement and such Customs Duties shall be eliminated as from April 1, 2010; (d) Customs Duties on originating goods classified under the tariff items indicated with “B4” shall be eliminated in 4 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (e) Customs Duties on originating goods classified under the tariff items indicated with “B5” shall be eliminated in 5 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (f) Customs Duties on originating goods classified under the tariff items indicated with “B6” shall be eliminated in 6 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (g) Customs Duties on originating goods classified under the tariff items indicated with “B7” shall be eliminated in 7 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; 136 (h) Customs Duties on originating goods classified under the tariff items indicated with “B8” shall be eliminated in 8 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (i) Customs Duties on originating goods classified under the tariff items indicated with “C” shall be eliminated in 10 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (j) Customs Duties on originating goods classified under the tariff items indicated with “Ca” shall be eliminated in 11 equal annual installments from the Base Rate to free, as from the date of entry into force of this Agreement; (k) Customs Duties on originating goods classified under the tariff items indicated with “D” shall be the most-favored-nation applied rate as of January 1, 2004 as from the date of entry into force of this Agreement and such Customs Duties shall be eliminated in 6 equal annual installments from the Base Rate to free, as from the first day of the sixth year; (l) Customs Duties on originating goods classified under the tariff items indicated with “E” shall be eliminated as from the first day of the eleventh year; (m) Customs Duties on originating goods classified under the tariff items indicated with “P” shall be reduced to the rate specified in the note indicated in Column 5 in each Party’s Schedule as from the date of entry into force of this Agreement; (n) Customs Duties on originating goods classified under the tariff items indicated with “Q” shall be as provided for in the terms and conditions set out in the note indicated in Column 5 in each Party’s Schedule; and (o) The originating goods classified under the tariff items indicated with “X” shall be excluded from any reduction or elimination of Customs Duties. 137 2. For the purposes of the elimination or reduction of Customs Duties in accordance with this Annex, any fraction less than 0.1 of a percentage point shall be rounded down in the cases of ad valorem duties, and any fraction less than 0.01 of the official monetary unit of the Party shall be rounded down in the cases of specific duties. This shall not be applied to the case of Customs Duties on originating goods classified in HS 0203.12, 0203.19, 0203.22, 0203.29, 0206.49, 0210.11, 0210.12, 0210.19, 0703.10, 1602.41, 1602.42, 1602.49, 7901.11 and 7901.12, derived from the difference between the value for Customs Duty and the value specified in Note 2 (b) or Column 3 of the Schedule of Japan in Section 2. 3. This Annex is made based on the Harmonized System, as amended on January 1, 2002. 4. For the purposes of subparagraphs 1(d) through (k) of this Section, Base Rate, as specified in Column 3 of each Party’s Schedule, means starting point of equal annual installments of elimination of Customs Duties. 5. For the purposes of implementing equal annual installments for this Section and Section 2 of this Annex, the following shall apply: (a) The reduction for the first year shall take place on the date of entry into force of this Agreement; and (b) The subsequent annual reductions shall take place on April 1 of each following year. 6. Except otherwise provided for in subparagraph 1(k) above, for the purposes of implementing equal annual installments for this Section and Section 3 of this Annex, the reductions shall take place on an annual basis, beginning the date of entry into force of this Agreement. 7. For the purposes of this Section and Section 2 of this Annex, the term “year” means, with respect to the first year, the period from the date of entry into force of this Agreement until the coming March 31 and, with respect to each subsequent year, the twelve-month period which starts on April 1 of that year. 8. For the purposes of this Section and Section 3 of this Annex, the term “year” means each twelve-month period starting on the date of entry into force of this Agreement. 138 Section 2 Schedule of Japan Notes for Schedule of Japan The terms and conditions in the following notes indicated with a serial number from 1 through 32 shall apply to originating goods imported from Mexico specified with that number in the Column 5 of the Schedule. The originating goods imported from Mexico specified with the letter “R” indicated in the Column 5 of the Schedule mean the goods with regard to which after the third year, the Parties shall enter into consultation in accordance with subparagraph 3(a)(i) of Article 5. On the request of either Party, the Parties shall consult on the facilitation of trade in fish and fishery products classified under Chapter 3 or 16 of the Harmonized System. The Parties may invite, by mutual consent, representatives from the private sector to the consultations. 1. Japan shall apply a tariff rate quota, in accordance with the following: (a) For the first year and the second year, the aggregate quota quantity shall be 10 metric tons for each year and the in-quota rate of Customs Duties shall be free. (b) From the third year to the fifth year, the aggregate quota quantity shall be as follows, respectively: (i) 3,000 metric tons for the third year; (ii) 4,000 metric tons for the fourth year; and (iii) 6,000 metric tons for the fifth year. The in-quota rate of Customs Duties applied during the period from the third year to the fifth year shall be negotiated by the Parties in the second year, in accordance with subparagraph 3(a)(i) of Article 5. The in-quota rate of Customs Duties for that period shall be lower than the most-favored-nation applied rate of Customs Duty in effect at the beginning of the Japanese fiscal year 2003 by at least 10 percent of that most-favored-nation applied rate. 139 (c) For the purposes of subparagraphs (a) and (b) above, the tariff rate quota shall be implemented through a certificate of tariff rate quota issued by the importing Party on the basis of the certificate issued by the exporting Party for each export. In the case of subparagraph (a) above, the certificates shall be issued for marketing and sales promotion. Both Parties shall avoid undue delay in the issuance of these certificates. On the request of either Party, the Parties shall consult as soon as possible to resolve any matter arising related to the issuance of the certificates or other administrative issues. (d) In accordance with subparagraph 3(a)(i) of Article 5, the Parties shall consult in the fifth year to consider the aggregate quota quantity of the tariff rate quota and in-quota rate after the fifth year, taking into consideration among others, the quota quantity during the fifth year and records of trade between the Parties. In the absence of agreement between the Parties and until such an agreement is reached as a result of the consultation, the aggregate quota quantity and in-quota rate for the fifth year shall be applied. (e) The tariff emergency measures on beef, stipulated in Article 7-5 of Temporary Tariff Measures Law of Japan (Law No. 36 of 1960), as may be amended, shall not be applied to the originating goods imported under this tariff rate quota. 2. Japan shall apply a tariff rate quota, in accordance with the following: (a) From the first year to the fifth year, the aggregate quota quantity shall be as follows, respectively: (i) 38,000 metric tons for the first year; (ii) 53,000 metric tons for the second year; (iii) 65,000 metric tons for the third year; (iv) 74,000 metric tons for the fourth year; and (v) 80,000 metric tons for the fifth year.
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Factors Influencing Pesticide Resistance in Psylla Pyricola Foerster and Susceptibility Inits Mirid
    AN ABSTRACT OF THE THESIS OF: Hugo E. van de Baan for the degree ofDoctor of Philosopbv in Entomology presented on September 29, 181. Title: Factors Influencing Pesticide Resistance in Psylla pyricola Foerster and Susceptibility inits Mirid Predator, Deraeocoris brevis Knight. Redacted for Privacy Abstract approved: Factors influencing pesticide susceptibility and resistance were studied in Psylla pyricola Foerster, and its mirid predator, Deraeocoris brevis Knight in the Rogue River Valley, Oregon. Factors studied were at the biochemical, life history, and population ecology levels. Studies on detoxification enzymes showed that glutathione S-transferase and cytochrome P-450 monooxygenase activities were ca. 1.6-fold higherin susceptible R. brevis than in susceptible pear psylla, however, esterase activity was ca. 5-fold lower. Esterase activity was ca. 18-fold higher in resistant pear psylla than in susceptible D. brevis, however, glutathione S-transferase and cytochrome P-450 monooxygenase activities were similar. Esterases seem to be a major factor conferring insecticideresistance in P. Pvricola. Although the detoxification capacities of P. rivricola and D. brevis were quite similar, pear psylla has developed resistance to many insecticides in the Rogue River Valley, whereas D. brevis has remained susceptible. Biochemical factors may be important in determining the potential of resistance development, however, they are less important in determining the rate at which resistance develops. Computer simulation studies showed that life history and ecological factors are probably of greater importancein determining the rate at which resistance develops in P. pvricola and D. brevis. High fecundity and low immigration of susceptible individuals into selected populations appear to be major factors contributing to rapid resistance development in pear psylla compared with D.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Wool Fiber Dyeing Machine Operator Course Code: TC WOOL 04
    Government of India Ministry of Textiles Textiles Committee Course Name: Wool Fiber Dyeing Machine Operator Course Code: TC WOOL 04 Version: 01 Developed by: Resource Support Agency (RSA), Textiles Committee, Ministry of Textiles, Government of India TABLE OF CONTENTS 1. Basic Textile Wet Processing Terms . 01 2. Brief of all Wet Processing Stages . 06 2.1. Grey Fabric Inspection . 07 2.2. Stitching . 07 2.3. Brushing . 07 2.4. Shearing/Cropping . 07 2.5. Singeing . 07 2.6. Desizing . 08 2.7. Scouring . 08 2.8. Bleaching . 09 2.10. Heat Setting . 09 2.11. Dyeing . 09 2.12. Printing . 11 2.13. Finishing . 11 2.14. Quality Assurance Laboratory . 12 2.15. Effluent Treatment Plant . 12 3. Introduction to Wool . 13 3.1. What is Wool? . 13 3.2. Types of Wool . 13 4. Composition of Wool . 15 4.1. Chemical Structure of Wool . 15 4.2. Morphological Structure of Wool . 16 5. Properties of Wool . 18 5.1. Physical properties of wool . 18 5.2. Chemical Properties of Wool . 19 5.3. End-Use Properties of Wool . 20 5.3.1 Uses and Application of Wool Fibres . 21 5.3.2 End Uses of Wool Fibres . 21 6. Wool Manufacturing Process . 22 Course: Wool Fiber Dyeing Machine Operator Developed by: Textiles Committee, Ministry of Textiles, Govt. of India 6.1. Flow Chart of Wool Processing . 22 6.2. Wool Manufacturing Processes . 22 6.2.1. Shearing . 23 6.2.2. Grading and Sorting . 23 6.2.3. Cleaning and Scouring . 24 6.2.4. Carding . 24 6.2.5.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Folic Acid, Pyridoxine, and Cyanocobalamin Combination
    ORIGINAL INVESTIGATION Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women The Women’s Antioxidant and Folic Acid Cardiovascular Study William G. Christen, ScD; Robert J. Glynn, ScD; Emily Y. Chew, MD; Christine M. Albert, MD; JoAnn E. Manson, MD Background: Observational epidemiologic studies indi- and visually significant AMD, defined as confirmed in- cate a direct association between homocysteine concentra- cident AMD with visual acuity of 20/30 or worse attrib- tion in the blood and the risk of age-related macular degen- utable to this condition. eration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are Results:Afteranaverageof7.3yearsoftreatmentandfollow- lacking. Our objective was to examine the incidence of AMD up, there were 55 cases of AMD in the combination treat- in a trial of combined folic acid, pyridoxine hydrochloride ment group and 82 in the placebo group (relative risk, 0.66; (vitamin B6), and cyanocobalamin (vitamin B12) therapy. 95% confidence interval, 0.47-0.93 [P=.02]). For visually significant AMD, there were 26 cases in the combination Methods: We conducted a randomized, double-blind, treatment group and 44 in the placebo group (relative risk, placebo-controlled trial including 5442 female health care 0.59; 95% confidence interval, 0.36-0.95 [P=.03]). professionals 40 years or older with preexisting cardio- vascular disease or 3 or more cardiovascular disease risk Conclusions: These randomized trial data from a large factors. A total of 5205 of these women did not have a cohort of women at high risk of cardiovascular disease diagnosis of AMD at baseline and were included in this indicate that daily supplementation with folic acid, pyri- analysis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0034530 A1 Fantz (43) Pub
    US 2013 0034530A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0034530 A1 Fantz (43) Pub. Date: Feb. 7, 2013 (54) DIETARY SUPPLEMENT COGNITIVE (52) U.S. Cl. ....................................... 424/94.2; 424/643 SUPPORT SYSTEM (57) ABSTRACT (75) Inventor: David Robert Fantz, Denver, CO (US) The present invention relates to a nutritional Supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3. Thiamin, Riboflavin, Niacin, Vita (73) Assignee: David R. Fantz, Denver, CO (US) min B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Car (21) Appl. No.: 13/456,287 nitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylala nine, Taurine, Methionine, Valine, Isoleucine, 5 Hydrox (22) Filed: Apr. 26, 2012 ytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L- Cysteine, Alpha Lipoic Acid, Alpha Related U.S. Application Data Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, (60) Provisional application No. 61/480.372, filed on Apr. Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax 29, 2011. Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, Publication Classification acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, Sour cherry, black raspberry), Organic (51) Int. Cl. freeze dried greens blends (barley grass, broccoli, beet, car A6 IK33/30 (2006.01) rot, alfalfa, oat), and Protein digestive enzyme blends (Pro A6IP3/02 (2006.01) tease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L A6IP 25/00 (2006.01) planatrum, B bifidum) in a mixture to provide optimal cog A6 IK38/54 (2006.01) nitive function.
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • R Graphics Output
    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 Lorber Et Al
    US 200601 10449A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 LOrber et al. (43) Pub. Date: May 25, 2006 (54) PHARMACEUTICAL COMPOSITION Publication Classification (76) Inventors: Richard R. Lorber, Scotch Plains, NJ (US); Heribert W. Staudinger, Union, (51) Int. Cl. NJ (US); Robert E. Ward, Summit, NJ A6II 3/473 (2006.01) (US) A6II 3L/24 (2006.01) Correspondence Address: A6IR 9/20 (2006.01) SCHERING-PLOUGH CORPORATION (52) U.S. Cl. ........................... 424/464; 514/290: 514/540 PATENT DEPARTMENT (K-6-1, 1990) 2000 GALLOPNG HILL ROAD KENILWORTH, NJ 07033-0530 (US) (57) ABSTRACT (21) Appl. No.: 11/257,348 (22) Filed: Oct. 24, 2005 The present invention relates to formulations useful for Related U.S. Application Data treating respiratory disorders associated with the production of mucus glycoprotein, skin disorders, and allergic conjunc (60) Provisional application No. 60/622,507, filed on Oct. tivitis while substantially reducing adverse effects associ 27, 2004. Provisional application No. 60/621,783, ated with the administration of non-selective anti-cholin filed on Oct. 25, 2004. ergic agents and methods of use thereof. US 2006/01 10449 A1 May 25, 2006 PHARMACEUTICAL COMPOSITION example, Weinstein and Weinstein (U.S. Pat. No. 6,086,914) describe methods of treating allergic rhinitis using an anti CROSS REFERENCE TO RELATED cholinergic agent with a limited capacity to pass across lipid APPLICATION membranes, such as the blood-brain barrier, in combination with an antihistamine that is limited in both sedating and 0001. This application claims benefit of priority to U.S.
    [Show full text]
  • Toxicological Profile for Hydrogen Sulfide and Carbonyl Sulfide
    HYDROGEN SULFIDE AND CARBONYL SULFIDE 149 6. POTENTIAL FOR HUMAN EXPOSURE 6.1 OVERVIEW Hydrogen sulfide has been found in at least 34 of the 1,832 waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) and carbonyl sulfide was detected in at least 4 of the 1,832 waste sites (ATSDR 2015). However, the number of sites evaluated for these substances is not known and hydrogen sulfide and carbonyl sulfide are ubiquitous in the atmosphere. The frequency of these sites can be seen in Figures 6-1 and 6-2. Carbonyl sulfide and hydrogen sulfide are principal components in the natural sulfur cycle. Bacteria, fungi, and actinomycetes (a fungus-like bacteria) release hydrogen sulfide during the decomposition of 2- sulfur containing proteins and by the direct reduction of sulfate (SO4 ). Hydrogen sulfide is also emitted from volcanoes, stagnant or polluted waters, and manure or coal pits with low oxygen content (Aneja 1990; Khalil and Ramussen 1984). The majority of carbonyl sulfide that enters the environment is released to air and it is very abundant in the troposphere (Conrad and Meuser 2000; EPA 1994c, 1994d; Meinrat et al. 1992; Simmons et al. 2012; Stimler et al. 2010). It enters the atmosphere from both natural and anthropogenic sources (EPA 1994c, 1994d; Meinrat et al. 1992; Stimler et al. 2010). Carbonyl sulfide is released from wetlands, salt marshes, soil, oceans, deciduous and coniferous trees, and volcanic gases (Blake et al. 2004; EPA 1994c, 1994d; Meinrat et al. 1992; Rasmussen et al. 1982a, 1982b; Stimler et al.
    [Show full text]